Gilead Sciences stock has climbed toward the upper end of its recent range, while fresh analyst data

Gilead Sciences stock stays firm after August 3, 2026 results showed revenue of $7.80 billion and EP

Gilead Sciences draws attention as stronger revenue, dividend support and institutional participation meet earnings pressure and pharmaceutical pipeline risks.

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Investment analysts at Erste Group Bank upped their FY2026 earnings per share estimates for shares of Gilead Sciences in a research note issued on Thursday, August 27th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical c

Railway Pension Investments Ltd trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,295,596 shares of the biopharmaceutical company

Shares of Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-nine ratings firms that are currently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a hold rating and twenty-four have given a b

Ancora Advisors LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 121,465 shares of the biopharmaceutical company

Gilead Sciences stock trades in the mid-$140s as of late August 2026, with fresh HIV and breast canc

Quantitative Investment Management LLC reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,223 shares of the biophar

Headlands Technologies LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 49,478 shares of the biopharmaceutical company